激活β2上腺素受体可以通过表观遗传机制防止AD类型的协同毒性
Ming Jin1, Zhiyun Wei1, Nagendran Ramalingam1
1Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Molecular psychiatry
|June 26, 2023
概括
激活β-2上腺素受体 (β2-AR) 增强海马突触可塑性,并防止粉样β毒性. 这一途径涉及基因素乙化,为阿尔茨海默病 (AD) 提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 丰富的环境 (EE) 增强海马的突触可塑性,并通过β-2上腺素受体 (β2-AR) 信号传递减轻粉样ββ oligomer (oAβ) 的突触毒性.
- 基于EE介导的神经保护的精确分子机制仍然不完全理解.
研究的目的:
- 阐明β2-AR激活对oAβ诱导的突触功能障碍提供保护的详细机制.
- 调查素乙化在调解β2-AR激活的神经保护作用中的作用.
主要方法:
- 在小鼠海马CA1切片中,电生理学记录了现场刺激后突触潜能 (fEPSP).
- 使用β2-AR激动剂,β1-AR抗剂和基因素脱乙酶 (HDAC) 抑制剂的药理学操纵.
- 评估突触可塑性 (长期强化,LTP) 和oAβ诱导的突触功能障碍.
- 对HDAC2水平和炎症/神经炎退行标志物的分析,以应对治疗和β2-AR淘汰小鼠.
主要成果:
- 药理上的β2-AR激活,但不是β1-AR激活,通过增强LTP和防止oAβ诱导的突触功能障碍来模仿EE效应.
- HDAC 抑制剂复制了 EE 的益处,这种效应在 β2-AR 淘汰赛小鼠中不存在,涉及 β2-AR 调节基因素乙化.
- β2-AR激活或EE降低了海马的HDAC2水平,而oAβ增加了它们;β2-AR激动剂或HDAC抑制剂抵消了oAβ诱导的炎症和神经元退化.
结论:
- β2-AR激活通过调节基因组乙化,特别是通过降低HDAC2水平来保护oAβ介导的突触功能障碍.
- 向β2-AR是缓解阿尔茨海默病 (AD) 病理学的有希望的治疗途径.
相关概念视频
Adrenergic Receptors: β Subtype
1.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K
Desensitization and Tachyphylaxis
1.9K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.9K
Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
Adrenergic Receptors (Adrenoceptors): Classification
2.7K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.7K


